Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Boosted by HighTower Advisors LLC

HighTower Advisors LLC boosted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 11.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 123,477 shares of the biotechnology company’s stock after buying an additional 12,706 shares during the quarter. HighTower Advisors LLC owned approximately 0.10% of Arrowhead Pharmaceuticals worth $2,401,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ARWR. Squarepoint Ops LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at about $9,976,000. Avoro Capital Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock valued at $231,022,000 after purchasing an additional 333,333 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Arrowhead Pharmaceuticals by 232.5% during the third quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock valued at $5,677,000 after purchasing an additional 204,933 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 61.9% in the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock worth $13,755,000 after purchasing an additional 202,280 shares during the last quarter. Finally, abrdn plc lifted its holdings in shares of Arrowhead Pharmaceuticals by 61.3% in the 3rd quarter. abrdn plc now owns 401,146 shares of the biotechnology company’s stock worth $7,770,000 after purchasing an additional 152,476 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright increased their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, November 27th. Piper Sandler dropped their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $21.85 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $17.05 and a 12 month high of $39.83. The firm has a market capitalization of $2.72 billion, a PE ratio of -4.35 and a beta of 0.91. The company’s 50 day simple moving average is $20.98 and its 200 day simple moving average is $23.15. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.